NC
SCLN

Nexthera Capital’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Nexthera Capital’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-65,000
Closed -$598K – 54
2015
Q4 		$598K Buy
+65,000
New +$544K 0.85% 20

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nexthera Capital's SCLN Position: Q1 2016 in Review

Nexthera Capital sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2016, closing a stake of 65,000 shares — an estimated $598K sold.

Nexthera Capital first reported a position in SCLN in Q4 2015 and held it in 1 quarter. The position peaked at $598K in Q4 2015. 142 funds tracked by Wall St. Rank hold SCLN as of Q1 2016.

  • Nexthera Capital reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Nexthera Capital sold 65,000 Sciclone Pharmaceuticals Inc shares in Q1 2016, an estimated $598K.
  • Nexthera Capital first reported a position in Sciclone Pharmaceuticals Inc in Q4 2015 and held it in 1 quarter.
  • Nexthera Capital's Sciclone Pharmaceuticals Inc position peaked at $598K in Q4 2015.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2016.

Based on Nexthera Capital's 13F filing for Q1 2016, filed 13 May 2016.